Oncolytics Biotech Inc (Oncolytics Biotech) is a clinical-stage biopharmaceutical company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company operates within the biotechnology and pharmaceutical industries, primarily targeting cancer treatment through innovative immunotherapy solutions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Oncolytics has been actively engaged in research and development initiatives focusing on the therapeutic potential of pelareorep, an oncolytic virus. The company's R&D efforts are centered around understanding and enhancing pelareorep's anti-tumor activity through three complementary modes of action: selective viral replication in cancer cells, modification of the tumor microenvironment, and induction of adaptive immune responses. Preclinical and clinical studies have demonstrated pelareorep's efficacy in various cancer models, including breast and pancreatic cancers, and its potential to improve patient outcomes when combined with other therapies such as chemotherapy and immunotherapy. The company is also exploring Pelareorep's role in gastrointestinal cancers through the GOBLET platform study and has initiated collaborations to further its research. The R&D unit of Oncolytics Biotech Inc is responsible for managing the company's research and development activities, which include conducting preclinical and clinical trials, analyzing data, and developing strategies to enhance the therapeutic efficacy of pelareorep. The unit plays a crucial role in advancing the company's pipeline products and exploring new therapeutic combinations and indications. As of December 2024, Oncolytics holds 147 issued patents, including 12 in the U.S. and 7 in Canada, with 14 patents pending in various jurisdictions. The company has an extensive patent portfolio covering pelareorep, its formulations, manufacturing methods, and screening techniques. The company's pipeline includes ongoing clinical trials for pelareorep in breast and gastrointestinal cancers, among others. The company has also entered collaborations, such as with the Global Coalition for Adaptive Research, to explore new therapeutic approaches. In FY2024, the company incurred an expense of CAD21.6 million on its R&D, which grew 22.2%YoY.